These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 31168016)

  • 21. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emicizumab for hemophilia A without inhibitors.
    Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
    Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
    [No Abstract]   [Full Text] [Related]  

  • 23. Emicizumab for the treatment of acquired hemophilia A.
    Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
    Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report.
    Al-Banaa K; Alhillan A; Hawa F; Mahmood R; Zaki A; El Abdallah M; Zimmerman J; Musa F
    Am J Case Rep; 2019 Jul; 20():1046-1048. PubMed ID: 31318850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.
    Yacoub OA; Duncan EM
    Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
    Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
    Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
    Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
    Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
    Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
    Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations.
    Yada K; Nogami K
    J Blood Med; 2019; 10():171-181. PubMed ID: 31308776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A.
    Lippi G; Favaloro EJ
    Adv Clin Chem; 2019; 88():151-167. PubMed ID: 30612605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Successful treatment by switching from activated prothrombin complex concentrate to emicizumab therapy in a hemophilia A patient with inhibitors].
    Sakamoto A; Nakadate H; Watanabe N; Ishiguro A
    Rinsho Ketsueki; 2020; 61(6):617-620. PubMed ID: 32624534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
    Castaman G; Santoro C; Coppola A; Mancuso ME; Santoro RC; Bernardini S; Pugliese FR; Lubrano R; Golato M; Tripodi A; Rocino A; Santagostino E; ; Biasoli C; Borchiellini A; Catalano A; Contino L; Coluccia A; Cultrera D; De Cristofaro R; Di Minno G; Fabbri A; Franchini M; Gamba G; Giuffrida AC; Gresele P; Giampaolo A; Hassan HJ; Luciani M; Marchesini E; Marino R; Mazzucconi MG; Molinari AC; Morfini M; Notarangelo LD; Peccarisi L; Peyvandi F; Pollio B; Rivolta GF; Ruggieri MP; Sargentini V; Schiavoni M; Sciacovelli L; Serino ML; Siragusa S; Tagliaferri A; Testa S; Tosetto A; Zampogna S; Zanon E
    Blood Transfus; 2020 Mar; 18(2):143-151. PubMed ID: 31657709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emicizumab for hemophilia A with factor VIII inhibitors.
    Young G; Callaghan M; Dunn A; Kruse-Jarres R; Pipe S
    Expert Rev Hematol; 2018 Nov; 11(11):835-846. PubMed ID: 30278802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Congenital hemophilia: a new treatment paradigm].
    Shima M
    Rinsho Ketsueki; 2019; 60(6):647-658. PubMed ID: 31281158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.